Publisher’s Note: Tomorrow at 2 pm ET, CJ is joined by special guest Matt McCall—one of Wall Street’s most respected innovation investors.
Fox Business’s Neil Cavuto once called Matt “one of my best guests” for his ability to cut through the noise and uncover opportunity before the crowd. For more than 25 years,
Matt has helped investors identify transformational trends years before they became household names.
Tomorrow, CJ and Matt will discuss whether AI resembles previous investment bubbles and how to separate short-term hype from the innovations that could shape the next decade.
Stephen Prior, Publisher
CVS was a wreck two years ago. Now it’s one of the best charts on the board.
Go back to 2024, and this was a stock people were running from. CVS owns Aetna, the health insurer, and Aetna was hemorrhaging money because patients were using way more care than the company had priced for.
It cut its profit outlook three quarters in a row, then gave up and pulled its guidance completely, and the CEO was gone by October. The stock fell to the high $50s and got left for dead.
Then the company did the hard, boring work. It dumped the money-losing insurance plans, walked away from the Obamacare money pit, and got a grip on costs.
By this spring, the numbers had flipped so hard that instead of cutting guidance, CVS was raising it. The stock has more than doubled off those lows.
Start with the trend. The EMAs are stacked on the daily, the 8 over the 21 over the 34, and the price is holding above all of them. It’s been grinding higher along those 8 and 21 for months, rather than spiking and stalling.
The weekly EMAs are stacked the same way. When the daily and the weekly line up like that, the trend is doing exactly what you want.
Then the squeeze. There’s a squeeze on, which just means the stock coiled up tight and quiet before its next move, and the momentum behind it is still pushing higher instead of fading. Stacked EMAs with a squeeze firing is the setup. That’s the whole thing I look for.
The pattern backs it up. It’s been basing up near the highs rather than rolling over, and a tight base like that is usually a good sign.
Your Action Plan
Earnings are the thing to watch.
CVS reports on August 5, before the open.
The options will be pricey into that print because they price in the earnings move, so it’s one to keep an eye on rather than chase.
There’s also a Medicare rate decision that already broke its way for 2027, and it starts selling the weight-loss drug Zepbound through its pharmacy business on October 1.
And it’s not moving in a vacuum.
Money’s been rotating out of the crowded tech and AI names into healthcare, and CVS is one of the charts catching that flow.
A name that’s stacked and squeezing, sitting in the group the money’s moving into, is the kind of thing I want on the list.
If you want to know how else I’m finding trades, you’ll want to check this out.